International Stem Cell ISCO
OTC ISCO
$0.21 -0.05 (-19.23%)
As of: Oct 21, 2026 · 10:19 AM EDT

International Stem Cell (ISCO) EV to EBITDA (2022 - 2026)

Updated

International Stem Cell's (ISCO) EV to EBITDA came in at 4.11 for Q2 2026, up 47.1% from 2.80 a year earlier.

Analysis

International Stem Cell (ISCO) EV to EBITDA (2022 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, EV to EBITDA at International Stem Cell was -23.31; for FY2024, it came in at -4.27.

  • In prior years, International Stem Cell's EV to EBITDA was 19.97 in FY2022.
  • The Q2 2026 figure stands as the highest quarterly EV to EBITDA since Q1 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.68 Bn 1,105.26 Bn 19.71 Bn
2 Johnson & Johnson 617.43 Bn 535.95 Bn 17.26 Bn
3 AbbVie 501.53 Bn 474.64 Bn 12.70 Bn
4 Merck 368.15 Bn 322.53 Bn 12.21 Bn
5 Novartis Ag 297.54 Bn 261.53 Bn 11.24 Bn
6 Astrazeneca 260.75 Bn 234.43 Bn 12.86 Bn
7 Amgen 236.53 Bn 191.93 Bn 7.24 Bn
8 Gilead Sciences 191.10 Bn 165.30 Bn 6.22 Bn
9 Pfizer 169.66 Bn 116.31 Bn 10.94 Bn
10 International Stem Cell 1.68 Mn -2.29 Mn 1.46 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 4.11
Sep 30, 2025 0.24
Jun 30, 2025 2.80
Mar 31, 2025 -4.59
Dec 31, 2024 -4.27
Sep 30, 2023 -23.47
Mar 31, 2023 71.11
Dec 31, 2022 19.97
API Access

International Stem Cell EV to EBITDA API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-ebitda&ticker=ISCO&period=max&api_key=YOUR_API_KEY